MetaCap

Madrigal Pharmaceuticals (MDGL) vs Dr. Reddy's Laboratories (RDY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dr. Reddy's Laboratories (RDY) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 7.0% versus a loss of 30.8%. Over five years, MDGL leads with a +362.0% price change compared with +18.2% for RDY. Dr. Reddy's Laboratories is the larger company by market cap ($12.41 billion vs $8.81 billion), about 1.4 times the size, while Madrigal Pharmaceuticals is growing revenue faster (+432.1% vs +13.8%).

On valuation, Dr. Reddy's Laboratories trades at a lower forward P/E (22.5x vs 36.5x for Madrigal Pharmaceuticals). Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Madrigal Pharmaceuticals does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -30.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MDGL-30.82%RDY+7.05%
+13%-10%-33%
Nov 21, 20251 yearNov 20, 2026
MDGL+360.07%RDY+19.43%
+660%+298%-64%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MDGL versus RDY key metrics
MetricMDGLRDY
Share price$379.10$14.89
Market cap$8.81B$12.41B
1-day change-4.45%+0.40%
YTD return-34.90%+6.05%
1-year return-30.82%+7.05%
5-year return+361.98%+18.19%
P/E ratio (TTM)—41.36
Forward P/E36.5222.47
EPS (TTM)$-5.85$0.36
Dividend yield0.00%53.73%
Annual dividend$0.00$8.00
Revenue (latest FY)$958.40M$3.81B
Revenue growth (YoY)+432.05%+13.76%
Net income (latest FY)$-288.28M$663.00M
Gross margin—58.51%
Operating margin-31.31%22.09%
Net margin-30.08%17.40%
52-week high$615.00$15.67
52-week low$353.54$11.36
Distance from 52-week high-38.36%-4.98%
Analyst consensusstrong_buybuy
Avg. price target upside+81.69%+0.20%
Average volume370.07K2.85M
Shares outstanding23.23M833.66M
Employees91527,527
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RDY has outperformed MDGL by 37.9 percentage points over the past year.
  • Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).
  • Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
  • Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +13.76%).

About Madrigal Pharmaceuticals

MDGL stock →

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.

Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees

About Dr. Reddy's Laboratories

RDY stock →

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees

MDGL vs RDY FAQ

Which is bigger, Madrigal Pharmaceuticals or Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $12.41B compared with $8.81B for Madrigal Pharmaceuticals (MDGL).

Which stock has performed better over the past year, MDGL or RDY?

RDY returned +7.05% over the past 12 months, compared with -30.82% for MDGL (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Madrigal Pharmaceuticals or Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Madrigal Pharmaceuticals does not currently pay a regular dividend.

Are Madrigal Pharmaceuticals and Dr. Reddy's Laboratories in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons